ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2023
Biogenic silver nanoparticles: in vitro activity against Staphylococcus aureus methicillin-resistant (MRSA) and multidrug-resistant coagulase-negative Staphylococcus (CoNS).
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Biogenic Silver Nanoparticle: In vitro antifungal activity against Sporothrix brasiliensis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Biogenic Silver Nanoparticles: An Antibacterial and Antibiofilm Approach to Control Carbapenem-Resistant Klebsiella pneumoniae.Current microbiology · 2026Article
- Sustainable microalgae-based Docosahexaenoic Acid-Silver nanoparticles for biomedical applications.Frontiers in bioengineering and biotechnology · 2026Article
- Harnessing biogenic nanoparticles for combating antibiotic resistance: green synthesis, mechanistic insights, and biotechnological applications.Frontiers in bioengineering and biotechnology · 2026Review
- Characterization of Silver Nanoparticles Synthesized Using Hypericum perforatum L. and Their Effects on Staphylococcus aureus.Microscopy research and technique · 2025Article
- Hydrogel Containing Biogenic Silver Nanoparticles andPharmaceutics · 2025Article
- Characteristics of Metallic Nanoparticles (Especially Silver Nanoparticles) as Anti-Biofilm Agents.Antibiotics (Basel, Switzerland) · 2024Review
- Unveiling the nanoworld of antimicrobial resistance: integrating nature and nanotechnology.Frontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) bacteria are one problem in health since the therapeutic alternative are reduced. For this, the application of nanotechnology through functionalized nanoparticles, like a biogenic silver nanoparticle (Bio-AgNP), obtained by biological synthesis, emerges as a possible alternative against the MDR bacteria. This study aimed to evaluate the antibacterial and antibiofilm activity of Bio-AgNP obtained for biological synthesis by Fusarium oxysporum strain 551 against methicillin-resistant Staphylococcus aureus (MRSA) and MDR coagulase-negative Staphylococcus (CoNS) isolates. Bio-AgNP has activity against S. aureus ATCC 25904, Staphylococcus epidermidis ATCC 35984, and MDR isolates, with minimal inhibitory concentration (MIC) ranging from 3.75 to 15 μg.mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.